---
title: "Kesimpta (ofatumumab) in relapsing multiple sclerosis: Pharmacology questions"
description: "Pharmacology questions on Kesimpta (ofatumumab) in relapsing multiple sclerosis, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Mechanism, Pharmacokinetics, and Components. Questions: How does Kesimpta work (mechanism of action)? How quickly does Kesimpta deplete B cells? How long after stopping Kesimpta do B cells recover? How long does Kesimpta stay in your system (half-life)? 3 further questions follow. 7 questions quoted from 2 sources."
canonical: "https://www.evicenter.com/medical-information/kesimpta--relapsing-multiple-sclerosis/pharmacology"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Kesimpta (ofatumumab) in relapsing multiple sclerosis: Pharmacology questions

Manufacturer: Novartis Pharmaceuticals Corporation  
Prescribing information: [Kesimpta](https://www.novartis.com/us-en/sites/novartis_us/files/kesimpta.pdf)

## Mechanism

<a id="kesimpta-mechanism"></a>

### How does Kesimpta work (mechanism of action)?

> “The precise mechanism by which ofatumumab exerts its therapeutic effects in multiple sclerosis is unknown, but is 
> presumed to involve binding to CD20, a cell surface antigen present on pre-B and mature B lymphocytes. Following cell 
> surface binding to B lymphocytes, ofatumumab results in antibody-dependent cellular cytolysis and complement-mediated 
> lysis.”

Source: [KESIMPTA: Prescribing information, page 9, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kesimpta.pdf#page=9)

> “KESIMPTA is thought to work by selectively binding to sites on both the small and large extracellular loops of CD20.<sup>4</sup>”

Source: [KESIMPTA: Mechanism of Action | MOA, captured 2026-11-13](https://www.kesimptahcp.com/resources/mechanism-of-action#:~:text=KESIMPTA%20is%20thought%20to%20work,and%20large%20extracellular%20loops%20of)

> “KESIMPTA causes CD20+ B cells to be vulnerable to both immediate and delayed B-cell lysis by mechanisms such as complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity<sup>4</sup>”

Source: [KESIMPTA: Mechanism of Action | MOA, captured 2026-11-13](https://www.kesimptahcp.com/resources/mechanism-of-action#:~:text=KESIMPTA%20causes%20CD20%2B%20B%20cells,complement%2Ddependent%20cytotoxicity%20and%20antibody%2Ddependent%20cellular)

<a id="kesimpta-b-cell-depletion"></a>

### How quickly does Kesimpta deplete B cells?

> “For B-cell counts, assays for CD19+ B-cells are used because the presence of ofatumumab interferes with the CD20 
> assay. In Study 1 and Study 2, KESIMPTA administered as recommended, resulted in a reduction of CD19+ B-cells to 
> below the LLN in 77.0% and 78.8% of patients, respectively, one week after treatment initiation, and in 95.0% and 95.8% 
> of patients, respectively, two weeks after treatment initiation [see Dosage and Administration (2.2) and Clinical Studies 
> (14)]. In Study 1 and Study 2, at Week 12, 99.3% to 99.5% of patients had CD19+ B-cell counts below LLN. The CD19+ 
> B-cell counts remained below LLN for approximately 97% of patients in Study 1 and 92% of patients in Study 2 from 12 
> weeks through 120 weeks while on KESIMPTA treatment.”

Source: [KESIMPTA: Prescribing information, page 9, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kesimpta.pdf#page=9)

<a id="kesimpta-b-cell-repletion"></a>

### How long after stopping Kesimpta do B cells recover?

> “Data from Studies 1 and 2 indicate a median time to B-cell recovery to either LLN or baseline value of 24.6 weeks post-
> treatment discontinuation. Pharmacokinetics and pharmacodynamics modeling and simulation for B-cell repletion 
> corroborate these data, predicting median time to B-cell recovery to LLN of 23 weeks post-treatment discontinuation.”

Source: [KESIMPTA: Prescribing information, page 9, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kesimpta.pdf#page=9)

## Pharmacokinetics

<a id="kesimpta-half-life"></a>

### How long does Kesimpta stay in your system (half-life)?

> “Ofatumumab is eliminated by both linear catabolic pathways and a non-linear B-cell mediated pathway, resulting in non-
> constant elimination half-life. Initially, a higher baseline B-cell count results in greater B-cell-mediated elimination and 
> shorter ofatumumab half-life. As the B-cells are depleted, the catabolic pathway predominates, resulting in a relatively 
> longer ofatumumab half-life compared to earlier in therapy when both elimination pathways were available. Following B-
> cell depletion, clearance was estimated to be 0.34 L/day following repeated subcutaneous administration of KESIMPTA 
> 20 mg injections. The half-life at steady state was estimated to be approximately 16 days following subcutaneous 
> administration of repeated KESIMPTA 20 mg dosage.”

Source: [KESIMPTA: Prescribing information, page 9, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kesimpta.pdf#page=9)

<a id="kesimpta-metabolism"></a>

### How is Kesimpta metabolized and eliminated?

> “Ofatumumab is a protein for which the expected metabolic pathway is degradation to small peptides and amino acids by 
> ubiquitous proteolytic enzymes.”

Source: [KESIMPTA: Prescribing information, page 9, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kesimpta.pdf#page=9)

> “Ofatumumab, a monoclonal antibody, is not likely to undergo renal excretion.”

Source: [KESIMPTA: Prescribing information, page 10, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kesimpta.pdf#page=10)

<a id="kesimpta-absorption"></a>

### How is Kesimpta absorbed after subcutaneous injection?

> “A subcutaneous dose of 20 mg every 4 weeks leads to a mean AUCtau of 483 mcg h/mL and a mean Cmax of 1.43 mcg/mL 
> at steady state. 
> After subcutaneous administration, ofatumumab is believed to be predominantly absorbed via the lymphatic system 
> similarly to other therapeutic monoclonal antibodies.”

Source: [KESIMPTA: Prescribing information, page 9, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kesimpta.pdf#page=9)

## Components

<a id="kesimpta-inactive-ingredients"></a>

### What are the inactive ingredients in Kesimpta?

> “Each 20 mg/0.4 mL KESIMPTA Sensoready Pen or prefilled syringe delivers 0.4 mL of solution. Each 0.4 mL contains 
> 20 mg of ofatumumab, and arginine (4 mg), disodium edetate (0.007 mg), polysorbate 80 (0.08 mg), sodium acetate”

Source: [KESIMPTA: Prescribing information, page 8, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kesimpta.pdf#page=8)

> “trihydrate (2.722 mg), sodium chloride (1.192 mg), and Water for Injection, USP with a pH of 5.5. Hydrochloric acid may 
> have been added to adjust pH.”

Source: [KESIMPTA: Prescribing information, page 9, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kesimpta.pdf#page=9)

## Related pages
- [Medical information: Kesimpta (ofatumumab): Relapsing multiple sclerosis](https://www.evicenter.com/medical-information/kesimpta--relapsing-multiple-sclerosis)
- [Indication](https://www.evicenter.com/medical-information/kesimpta--relapsing-multiple-sclerosis/indication)
- [Clinical trials](https://www.evicenter.com/medical-information/kesimpta--relapsing-multiple-sclerosis/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/kesimpta--relapsing-multiple-sclerosis/safety)
- [Specific populations](https://www.evicenter.com/medical-information/kesimpta--relapsing-multiple-sclerosis/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/kesimpta--relapsing-multiple-sclerosis/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/kesimpta--relapsing-multiple-sclerosis/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/kesimpta--relapsing-multiple-sclerosis/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/kesimpta--relapsing-multiple-sclerosis/access-and-coverage)
